TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Viva Biotech Holdings ( (HK:1873) ) has shared an update.
Viva Biotech Holdings, through its subsidiary Hangzhou Viva Zongchen, has entered into a Joint Venture Agreement to establish a new Fund focused on private equity investments in the pharmaceutical industry. The Fund, which has a term of seven years, will concentrate on early-stage development projects and technological innovation in life sciences. Hangzhou Viva Zongchen will invest RMB25.0 million as a limited partner. This strategic move positions Viva Biotech to leverage emerging opportunities in the pharmaceutical sector, potentially enhancing its industry standing and offering growth prospects for stakeholders.
More about Viva Biotech Holdings
Viva Biotech Holdings operates in the pharmaceutical industry, focusing on early-stage development projects and cutting-edge technological innovation in life sciences. The company engages in private equity investments, investments, and asset management, primarily targeting the pharmaceutical sector.
Average Trading Volume: 7,144,551
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.94B
Find detailed analytics on 1873 stock on TipRanks’ Stock Analysis page.